Want to see ABEO full AI Analyst Report?
Abeona Therapeutics (ABEO) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Non-Conforming Pz-Cel Surgical Application To Rdeb Wounds, Additional Biopsies, Pz-Cel Surgical Application To Deb Wounds | Epidermolysis Bullosa (Eb), Recessive Dystrophic Epidermolysis Bullosa (Rdeb), Dystrophic Epidermolysis Bullosa (Deb) | Phase IV | Not Yet Recruiting | Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds | Jul 16, 2026 | ― |
| Pz-Cel, Eb-101 Surgical Application Of Rdeb Wounds | Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Rdeb | Phase III | Active Not Recruiting | A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients | Jan 23, 2023 | ― |
| Eb-101 | Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Phase III | Completed | Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Jan 10, 2020 | ― |
| Abo-102 | Mps Iiia, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis Iii | phase1AndPhase2 | Terminated | Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease | Sep 11, 2019 | ― |
| Raav9.Cmv.Hnaglu | Mucopolysaccharidosis Type 3 B | phase1AndPhase2 | Terminated | Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB | Oct 10, 2017 | ― |
| Ux111, Prophylactic Immunomodulatory Therapy, Optimized Prophylactic Im Therapy, Adjuvant Im Therapy | Mps Iiia, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis Iii | phase2AndPhase3 | Recruiting | Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH | Mar 17, 2016 | ― |
| Lzrse-Col7a1 Engineered Autologous Epidermal Sheets | Epidermolysis Bullosa, Epidermolysis Bullosa Dystrophica | phase1AndPhase2 | Completed | Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa | Dec 15, 2010 | ― |
| Ofloxacin, Msi-78 | Diabetic Foot Ulcers | Phase III | Completed | MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers | Nov 21, 2007 | ― |
| Ofloxacin, Msi-78 | Diabetic Foot Ulcers | Phase III | Completed | MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers | Nov 21, 2007 | ― |
| Econail | Onychomycosis | Phase II | Completed | A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail | Oct 05, 2006 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Non-Conforming Pz-Cel Surgical Application To Rdeb Wounds, Additional Biopsies, Pz-Cel Surgical Application To Deb Wounds | Phase IV | Epidermolysis Bullosa (Eb), Recessive Dystrophic Epidermolysis Bullosa (Rdeb), Dystrophic Epidermolysis Bullosa (Deb) | Not Yet Recruiting | Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds | Jul 16, 2026 | ― |
| Pz-Cel, Eb-101 Surgical Application Of Rdeb Wounds | Phase III | Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Rdeb | Active Not Recruiting | A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients | Jan 23, 2023 | ― |
| Eb-101 | Phase III | Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Completed | Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Jan 10, 2020 | ― |
| Abo-102 | phase1AndPhase2 | Mps Iiia, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis Iii | Terminated | Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease | Sep 11, 2019 | ― |
| Raav9.Cmv.Hnaglu | phase1AndPhase2 | Mucopolysaccharidosis Type 3 B | Terminated | Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB | Oct 10, 2017 | ― |
| Ux111, Prophylactic Immunomodulatory Therapy, Optimized Prophylactic Im Therapy, Adjuvant Im Therapy | phase2AndPhase3 | Mps Iiia, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis Iii | Recruiting | Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH | Mar 17, 2016 | ― |
| Lzrse-Col7a1 Engineered Autologous Epidermal Sheets | phase1AndPhase2 | Epidermolysis Bullosa, Epidermolysis Bullosa Dystrophica | Completed | Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa | Dec 15, 2010 | ― |
| Ofloxacin, Msi-78 | Phase III | Diabetic Foot Ulcers | Completed | MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers | Nov 21, 2007 | ― |
| Ofloxacin, Msi-78 | Phase III | Diabetic Foot Ulcers | Completed | MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers | Nov 21, 2007 | ― |
| Econail | Phase II | Onychomycosis | Completed | A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail | Oct 05, 2006 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Abeona Therapeutics Inc (ABEO) have in its pipeline
Abeona Therapeutics ABEO is currently developing the following drugs: Non-Conforming Pz-Cel Surgical Application To Rdeb Wounds, Additional Biopsies, Pz-Cel Surgical Application To Deb Wounds, Pz-Cel, Eb-101 Surgical Application Of Rdeb Wounds, Eb-101, Abo-102, Raav9.Cmv.Hnaglu, Ux111, Prophylactic Immunomodulatory Therapy, Optimized Prophylactic Im Therapy, Adjuvant Im Therapy, Lzrse-Col7a1 Engineered Autologous Epidermal Sheets, Ofloxacin, Msi-78, Econail. These drug candidates are in various stages of clinical development as the company works toward FDA approval.